The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | TeliMET: exploring the competitive landscape of ABBV-400 and Teliso-V in c-MET NSCLC
Mariana Brandão, MD, PhD, Jules Bordet Institute, Brussels, Belgium, discusses the ongoing Phase III TeliMET trial (NCT04928846), which highlights the competitive landscape between ABBV-400 and its sister molecule, telisotuzumab vedotin (Teliso-V). Both agents share the same antibody and target but differ in their payloads and linkers. As ABBV-400 seeks to establish its niche among the array of c-MET-targeting agents, identifying a relevant biomarker will be crucial for its successful positioning in this competitive field. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
